Niranjan Rao

Summary

Publications

  1. ncbi Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study
    Niranjan Rao
    Forest Research Institute, Forest Laboratories, Inc, Jersey City, New Jersey, USA
    Clin Ther 27:1596-606. 2005
  2. ncbi The clinical pharmacokinetics of escitalopram
    Niranjan Rao
    Kyowa Pharmaceutical, Inc, Princeton, New Jersey 08540, USA
    Clin Pharmacokinet 46:281-90. 2007
  3. ncbi A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin
    N Rao
    Kyowa Pharmaceutical Inc, 212 Carnegie Center, Suite 101, Princeton, NJ 08540, USA
    J Clin Pharmacol 48:1092-8. 2008
  4. ncbi Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil
    Antonia P Periclou
    Clinical Pharmacology and Drug Dynamics, Forest Research Institute, Jersey City, NJ 07311 4994, USA
    Ann Pharmacother 38:1389-94. 2004
  5. ncbi Pharmacokinetic study of memantine in healthy and renally impaired subjects
    Antonia Periclou
    Forest Research Institute, Jersey City, NJ, USA
    Clin Pharmacol Ther 79:134-43. 2006

Detail Information

Publications5

  1. ncbi Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study
    Niranjan Rao
    Forest Research Institute, Forest Laboratories, Inc, Jersey City, New Jersey, USA
    Clin Ther 27:1596-606. 2005
    ..Given the renal tubular transport and extensive urinary excretion of memantine and metformin, it was of interest to assess the pharmacokinetic and pharmacodynamic interaction with glyburide/metformin...
  2. ncbi The clinical pharmacokinetics of escitalopram
    Niranjan Rao
    Kyowa Pharmaceutical, Inc, Princeton, New Jersey 08540, USA
    Clin Pharmacokinet 46:281-90. 2007
    ..The favourable pharmacokinetic profile of escitalopram suggests clinical utility in a broad range of patients...
  3. ncbi A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin
    N Rao
    Kyowa Pharmaceutical Inc, 212 Carnegie Center, Suite 101, Princeton, NJ 08540, USA
    J Clin Pharmacol 48:1092-8. 2008
    ..The lack of inhibition by istradefylline on metabolite systemic exposure, combined with increased atorvastatin systemic exposure, suggests a predominant P-glycoprotein inhibitory effect of istradefylline...
  4. ncbi Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil
    Antonia P Periclou
    Clinical Pharmacology and Drug Dynamics, Forest Research Institute, Jersey City, NJ 07311 4994, USA
    Ann Pharmacother 38:1389-94. 2004
    ..Memantine, a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist, was approved in the US for treatment of moderate to severe Alzheimer's disease in October 2003...
  5. ncbi Pharmacokinetic study of memantine in healthy and renally impaired subjects
    Antonia Periclou
    Forest Research Institute, Jersey City, NJ, USA
    Clin Pharmacol Ther 79:134-43. 2006
    ..Our objective was to evaluate the pharmacokinetics of the Alzheimer's disease treatment memantine in subjects with normal and impaired renal function...